Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor by Evans, Jemma et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prokineticin 1 mediates fetal-maternal dialogue regulating
endometrial leukemia inhibitory factor
Citation for published version:
Evans, J, Catalano, RD, Brown, P, Sherwin, R, Critchley, HOD, Fazleabas, AT & Jabbour, HN 2009,
'Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor' The
FASEB Journal, vol. 23, no. 7, pp. 2165-75. DOI: 10.1096/fj.08-124495
Digital Object Identifier (DOI):
10.1096/fj.08-124495
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
The FASEB Journal
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
The FASEB Journal • Research Communication
Prokineticin 1 mediates fetal-maternal dialogue
regulating endometrial leukemia inhibitory factor
Jemma Evans,*,1 Rob D. Catalano,*,1 Pamela Brown,* Rob Sherwin,‡
Hilary O. D. Critchley,† Asgerally T. Fazleabas,§ and Henry N. Jabbour*,2
*Medical Research Council Human Reproductive Sciences Unit and †Reproductive and
Developmental Sciences, Queen’s Medical Research Institute, Edinburgh, UK; ‡Department of
Pathology, University of Cambridge, Cambridge, UK; and §Department of Obstetrics and Gynecology,
University of Illinois, College of Medicine, Chicago, Illinois, USA
ABSTRACT Implantation requires communication be-
tween a receptive endometrium and a healthy blastocyst.
This maternal-embryonic crosstalk involves local media-
tors within the uterine microenvironment. We demon-
strate that a secreted protein, prokineticin 1 (PROK1), is
expressed in the receptive endometrium and during early
pregnancy. PROK1 induces expression of leukemia inhib-
itory factor (LIF) in endometrial epithelial cells and first
trimester decidua via a Gq-Ca2-cSrc-mitogen-activated
protein kinase kinase-mediated pathway. We show that
human embryonic chorionic gonadotropin (hCG) induces
sequential mRNA expression of PROK1 and LIF in an
in vivo baboon model, in human endometrial epithelial
cells, and in first-trimester decidua. We have used micro
RNA constructs targeted to PROK1 to demonstrate that
hCG-mediated LIF expression in the endometrium is
dependent on prior induction of PROK1. Dual immu-
nohistochemical analysis colocalized expression of the
luteinizing hormone/chorionic gonadotropin receptor,
PROK1, PROKR1, and LIF to the glandular epithelial
cells of the first trimester decidual tissue. PROK1
enhances adhesion of trophoblast cells to fibronectin and
laminin matrices, which are mediated predominantly via
LIF induction. These data describe a novel signaling
pathway mediating maternal-embryonic crosstalk, in
which embryonic hCG via endometrial PROK1 may play
a pivotal role in enhancing receptivity and maintaining
early pregnancy.—Evans, J., Catalano, R. D., Brown, P.,
Sherwin, R., Critchley, H. O. D., Fazleabas, A. T., Jab-
bour, H. N. Prokineticin 1 mediates fetal-maternal dia-
logue regulating endometrial leukemia inhibitory factor.
FASEB J. 23, 2165–2175 (2009)
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Differentiation of the endometrium is essential for
successful embryo implantation. The secretory phase
encompasses a finite period of time or “window” during
which the endometrium is optimally receptive for im-
plantation of a blastocyst. After this period, the endo-
metrium becomes refractory to conceptus implanta-
tion. The implantation window in humans is predicted
to last for 4 d and commences 6 d after the
luteinizing hormone (LH) peak in a normal menstrual
cycle (1, 2). The endometrial expression of a number
of cytokines, chemokines, growth factors, and adhesive
molecules is associated with the onset of receptivity. In
the event of pregnancy, embryonic human chorionic
gonadotropin (hCG) maintains corpus luteum-medi-
ated progesterone production, which is essential for the
maintenance of early pregnancy. Production of hCG by
the blastocyst may also directly regulate expression of
endometrial factors that may prolong the period dur-
ing which the endometrium is receptive (3–5).
Recently, the expression of a pleiotropic protein,
prokineticin 1 (PROK1), and its receptor, prokineticin
receptor 1 (PROKR1), has been characterized in the
nonpregnant and early pregnant human endometrium
(6, 7). Endometrial PROK1 expression peaks during
the secretory phase of the human menstrual cycle (6, 7)
and is further elevated during the first trimester of
pregnancy (7). PROK1 and PROKR1 are also expressed
in human early pregnancy tissues, with elevation in
expression between wk 8–9 of pregnancy and localiza-
tion to the syncytiotrophoblast and cytotrophoblast
layers (8). In addition, PROK1 has been demonstrated by
gene array analysis to regulate endometrial expression of
a host of genes known to be important for implantation,
including cyclooxygenase-2, heparin-binding epidermal
growth factor (EGF), Dickkopf-1, interleukin (IL)-11, and
leukemia inhibitory factor (LIF) (7). LIF is a cytokine that
is critical for murine implantation (9). LIF expression in
mice is initiated on d 4 of pregnancy before implantation,
after the nidatory estrogen peak (10) and in humans is
elevated during the receptive phase of the menstrual
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cycle (11, 12). However, the exact mechanisms regulat-
ing LIF expression during this phase of the menstrual
cycle in humans are not understood. In models of early
pregnancy, it has been established that hCG mediates
endometrial LIF expression in humans and baboons
(13, 14).
In this study we investigated the role of PROK1 in
the hCG-mediated regulation of LIF during embry-
onic to maternal crosstalk of early pregnancy. We
sought to identify the intracellular signaling path-
ways leading to enhancement of LIF expression and
evidence for a functional role of endometrial LIF in
early pregnancy events.
MATERIALS AND METHODS
Reagents
DMEM-F12 GlutaMAX culture medium and RPMI 1640 culture
medium were purchased from Invitrogen (Paisley, UK). LIF and
chorionic gonadotropin (CG) receptor antibodies were pur-
chased from Santa Cruz Biotechnology/Autogen Bioclear
(Calne, UK). PROK1 antibodies were purchased from Phoenix
Pharmaceuticals (Belmont, CA, USA). PROKR1 antibody was
purchased from Life Span Biosciences (Atlanta, GA, USA).
SuperFect transfection reagent was purchased from Qiagen
(Crawley, UK). Intracellular calcium chelator [1,2-bis(2-
aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethyl
ester (BAPTA-AM)] used at a final concentration of 50 M,
protein kinase C (PKC) inhibitor (Ro-318220) used at a final
concentration of 1 M, cSrc inhibitor [4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)] used
at a final concentration of 10 M, EGF receptor (EGFR)
inhibitor (AG1478) used at a final concentration of 200 nM,
MEK inhibitor (PD98059) used at a final concentration of 50
M, and protein synthesis inhibitor (cycloheximide) used at a
final concentration of 10 g/ml were purchased from Calbio-
chem (Nottingham, UK). Gq inhibitor (YM254890) used at a
final concentration of 1 M was kindly supplied by Dr. Jun
Takasaki (Molecular Medicine Laboratories, Yamanouchi Phar-
maceutical Co. Ltd., Tokyo, Japan). LIF ELISAs were purchased
from R&D Systems (Minneapolis, MN, USA). Recombinant LIF
used at a final concentration of 100 ng/ml and adhesion assays
were purchased from Chemicon (Chandlers Ford, UK). hCG
was purchased from Sigma (Dorset, UK). Recombinant hCG was
obtained from Dr. A. F. Parlow (National Hormone and Pitu-
itary Program, Harbor-UCLA Medical Center, Torrance, CA,
USA). Recombinant PROK1, used at a final concentration of 40
nM, was purchased from Promokine (Heidelberg, Germany).
Patients and tissue collection
Endometrial biopsies were obtained from women with regu-
lar menstrual cycles who had not received hormonal prepa-
rations in the 3 mo preceding biopsy collection and were
dated according to Noyes criteria by a pathologist. Circulating
estradiol and progesterone concentrations were measured
and were consistent with the histological assessment. First
trimester decidua (7–12 wk of gestation) was collected from
women undergoing elective first-trimester surgical termina-
tion of pregnancy with gestation confirmed by ultrasound
scan. Ethical approval was obtained from Lothian research
ethics committee, and written informed patient consent was
obtained before tissue collection.
Baboon tissue collection
Baboon tissues were treated as described previously and
subjected to microarray analysis (14). Briefly, uterine tissue
was obtained from 6 control and 5 hCG-treated adult female
baboons (Papio annubis). Tissue was collected by endometrec-
tomy or hysterectomy on d 10 postovulation (PO). Ovulation
was detected in cycling female baboons by measuring periph-
eral serum levels of estradiol beginning on d 7 after the first
day of menses. The day of estradiol surge was designated as d
1, with d 0 as the day of ovulatory LH surge and d 1 as the
day of ovulation. On d 6 PO, an oviductal cannula was
attached to an Alzet osmotic minipump, and recombinant
hCG was infused at the rate of 1.25 IU/h for 5 d. The infusion
was terminated on d 10 PO (d 10 corresponds to the expected
day of implantation in pregnant baboons). All experimental
procedures were approved by the animal care committee of
the University of Illinois (Chicago, IL, USA).
Cell/tissue culture and treatment
Ishikawa endometrial epithelial cells and JEG-3 epithelial
choriocarcinoma cells obtained from the European Collec-
tion of Cell Culture (Porton Down, UK) were routinely
maintained in DMEM-F12 GlutaMAX culture medium with
10% FBS, 100 IU of penicillin, and 100 g of streptomycin at
37°C and 5% CO2. PROKR1 stably transfected Ishikawa cells
were produced and maintained as described previously (7).
First trimester decidual tissue was chopped finely and main-
tained in DMEM. Tissue was divided into equal portions for
experimental procedures. Transient transfections of Ishikawa
cells were performed using PROK1 targeting microRNA
(miRNA) constructs. Tissue was infected with lentivirus ex-
pressing PROK1 miRNA constructs for 72 h. Oligonucleo-
tides encoding human PROK1 miRNA constructs were ob-
tained from Invitrogen and inserted into the pcDNA6.2-GW/
EmGFP-miR vector and used for transient transfections.
These were recombined to create plenti6/V5-EmGFP-miR-
neg control and pLenti6/V5-EmGFP-hum-PROK1-72 and
-287. Lentivirus was produced with a Block-iT lentiviral Pol II
miR RNAi expression system (Invitrogen) using the manufac-
turer’s protocols and used to infect tissue for 72 h. Cells and
tissue were incubated in serum-free medium overnight before
treatment with PROK1 or hCG alone or pretreated for 1 h
with inhibitors at the concentrations indicated above. Cells,
tissue, and medium were harvested, and RNA or protein was
extracted for PCR or ELISA analysis.
Immunohistochemistry and immunofluorescent microscopy
Colocalization of PROK1 with CG receptor or PROKR1 with LIF
was performed by dual immunofluorescence histochemistry.
Five-micrometer paraffin-embedded sections were dewaxed and
rehydrated in graded ethanol. Antigen retrieval was performed
by boiling in 0.01 M citrate buffer for 5 min. Endogenous
peroxidase activity was quenched by incubation in 3% H2O2/
MeOH solution. Sections were blocked using 5% normal horse
serum. Sections were incubated with goat anti-CG receptor
(K-15, sc-26341) (1:10) or goat anti-LIF (1:10) overnight at 4°C.
Sections were then incubated with horse anti-goat biotinylated
antibodies, followed by incubation with fluorochrome streptavi-
din 546 (1:200 in PBS). Sections were reblocked with 5% normal
goat serum (PROKR1/LIF localizations) or 5% normal swine
serum (PROK1/CG receptor localizations) and incubated
with rabbit anti-human PROK1 (1:1500) or rabbit anti-human
PROKR1 (1:500) overnight at 4°C. Sections were incubated
with peroxidase-labeled goat or swine anti-rabbit antibodies
(1:200 in PBS) followed by fluorochrome trichostatin A plus
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fluorescein (1:50 in substrate). Sections were washed and incu-
bated with nuclear counterstain ToPro (1:2000 in PBS),
mounted in PermaFluor, and photographed using a laser scan-
ning microscope (LSM 510; Carl Zeiss, Jena, Germany).
TaqMan quantitative RT-PCR
RNA was extracted with TRI reagent (Thermo Scientific,
Cramlington, UK) following the manufacturer’s guidelines
using phase lock tubes (Eppendorf, Cambridge, UK). RNA
samples were reverse transcribed as described previously (6).
PCR reactions were carried out using an ABI Prism 7900
system (Applied Biosystems, Foster City, CA, USA). Primer
and FAM (6-carboxyfluorescein)-labeled probe sequences are
listed in Table 1. Gene expression was normalized to 18S
ribosomal RNA (Applied Biosystems) as an internal standard.
Results are expressed as relative to a standard (endometrial
tissue cDNA) included in all reactions.
LIF measurement
PROKR1 Ishikawa cells and decidual tissue were treated with
40 nM PROK1 over a period of 24 h. Medium was removed
and assayed by ELISA for LIF following the manufacturer’s
instructions (R&D Systems). Briefly, medium or standards
were applied to the microplate coated with mouse anti-LIF
monoclonal antibody for 2 h at room temperature. Subse-
quently, polyclonal LIF antibody conjugated to horseradish
peroxidase was applied followed by the color development
solution (a 50:50 mix of stabilized hydrogen peroxidase and
stabilized tetramethylbezidine) for 20 min. Color develop-
ment was terminated by addition of sulfuric acid, and the
optical density was determined at 450 nm with correction at
540 nm. LIF ELISA values were normalized against total
protein content.
Protein extraction
Tissue was harvested in Nonidet P-40 lysis buffer, and protein
content was quantified according to the manufacturer’s in-
structions (Bio-Rad Laboratories, Hemel Hempstead, UK).
Adhesion assay
Conditioned medium was prepared by incubating PROKR1
Ishikawa cells with vehicle (PBS) or 40 nM PROK1 for 12 h.
PROK1- and vehicle-conditioned medium were immunoneutral-
ized by incubation overnight at 4°C in the presence of 1 g/ml
LIF antibody. JEG-3 cells were seeded to a density of 5 105 cells
and treated overnight with conditioned medium, immunoneu-
tralized conditioned medium, and 100 ng/ml recombinant LIF
or vehicle (PBS). Cells were subsequently trypsinized and sub-
jected to an adhesion assay according to the manufacturer’s
guidelines (Chemicon). Briefly, 5  104 cells/well were applied
to wells coated with fibronectin or laminin for 1 h at 37°C and
5% CO2. Wells were subsequently washed with PBS (with Ca
2
and Mg2) followed by addition of 10% crystal violet. Wells were
again washed, and cells were solubilized by addition of solubili-
zation buffer. Absorbance was determined at 540 nm.
Statistics
Data were subjected to statistical analysis with ANOVA and
Fisher’s protected least-significant differences tests (StatView
5.0; Abacus Concepts Inc., Berkeley, CA, USA) or the Wilcox-
on-Mann-Whitney test (GraphPad Prism, GraphPad Software,
Inc, LA Jolla, CA, USA) where appropriate.
RESULTS
PROK1 induces expression of LIF via a
Ca2-PKC-cSrc-EGFR-MEK-mediated pathway
Previous microarray analysis has revealed that LIF is a
target of transcriptional regulation by PROK1 via
PROKR1 (7). In this study, we examined the temporal
regulation and mechanism by which PROK1 mediates LIF
expression. Treatment of PROKR1 Ishikawa cells with 40
nM PROK1 resulted in a time-dependent increase in LIF
mRNA, peaking at 6 h (17.883.8-fold above vehicle-
treated control, P0.001) (Fig. 1A) and protein at 12 h
(27.83.97 pg/ml, P0.05) (Fig. 1B). No increase in LIF
mRNA expression was observed in the wild-type (WT) Ish-
ikawa cells at any time point (Fig. 1A). Cotreatment of
PROKR1 Ishikawa cells with 40 nM PROK1 and inhibitors of
Gq (YM254890), Ca2 (BAPTA-AM), PKC (Ro-318220),
cSrc (PP2), EGFR (AG1478), or MEK (PD98059) for 6 or
12 h significantly inhibited PROK1-mediated LIF mRNA
and protein expression (P0.001) (Fig. 1C, D).
hCG mediates expression of PROK1 and LIF
Previous studies have highlighted the fact that the
expression of LIF can be induced by hCG in a number
of models including primary cell cultures (13), human
endometrial infusion (15), and, most recently, a ba-
boon endometrial infusion model (14). Using RNA
extracted from baboon endometrium after treatment
with hCG for 5 d commencing on d 6 PO, we have
shown that hCG increases mRNA expression of PROK1
(5.20.3-fold above vehicle-treated control, P0.05)
(Fig. 2A).
To demonstrate the temporal regulation of PROK1
expression mediated by hCG, PROKR1 Ishikawa cells
were stimulated with 1 IU of hCG for 4, 6, 8, 12, 18,
and 24 h. PROK1 mRNA expression was elevated by
hCG with a peak in expression at 6 h (3.440.73-fold
above vehicle-treated control, P0.01) (Fig. 2B). LIF
TABLE 1. TaqMan primer and probe sequences for PROK1,
LIF, LH/CG receptor, and 18S ribosomal RNA
Gene Primers and probe (5-3)
PROK1 forward GTGCCACCCGGGCAG
PROK1 reverse AGCAAGGACAGGTGTGGTGC
PROK1 probe (FAM) ACAAGGTCCCCTTGTTCAGGAAACGCA
LIF forward TGGTGGAGCTGTACCGCATA
LIF reverse TGGTCCCGGGTGATGTTG
LIF probe (FAM) TCGTGTACCTTGGCACCTCCCTGG
CG receptor forward TGGCTGGGACTATGAATATGGTT
CG receptor reverse AGGGATTAAAAGCATCTGGTTCAG
CG receptor probe
(FAM) CTGCTTACCCAAGACACCCCGATGTG
18S forward CGGCTACCACATCCAAGGAA
18S reverse GCTGGAATTACCGCGGCT
18S probe (VIC) TGCTGGCACCAGACTTGCCCTC
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mRNA expression was also regulated by hCG in
PROKR1 Ishikawa cells, with a peak in LIF expression
at 16 h after treatment with hCG (2.030.3-fold
above vehicle-treated control, P0.05) (Fig. 2C). The
peak in hCG-mediated LIF mRNA expression oc-
curred 10 h after the peak in hCG-mediated
PROK1 mRNA. Cotreatment of PROKR1 Ishikawa
cells with 10 g/ml cycloheximide, an inhibitor of
protein synthesis, and 1 IU of hCG significantly
inhibited hCG-mediated LIF expression at 12, 16,
and 18 h (P0.01) (Fig. 2D), suggesting that an
intermediary protein is involved in hCG-mediated
LIF expression. To investigate whether PROK1 is
required for hCG-mediated LIF expression, we gen-
erated miRNA constructs expressing sequences tar-
geting PROK1. Transfection of PROKR1 Ishikawa
cells with pcDNA6.2-GW/EmGFP-PROK1-72 or
PROK1-287 miRNA constructs significantly inhibited
hCG-mediated PROK1 expression at 6 h compared with
that in PROKR1 Ishikawa cells transfected with scram-
bled control construct alone (P0.05) (Fig. 2E). More-
over, transfection of pcDNA6.2-GW/EmGFP-PROK1-72
or PROK1-287 into PROKR1 Ishikawa cells significantly
inhibited hCG-mediated LIF expression at 18 h (P0.05)
(Fig. 2F), suggesting that regulation of LIF expression by
hCG is mediated via the expression of PROK1.
Figure 1. PROK1 induces LIF mRNA and protein expression. LIF mRNA (A) and protein (B) expression in WT and PROKR1
Ishikawa cells after treatment with 40 nM PROK1. LIF mRNA and protein expression peaked at 6 and 12 h, respectively, in
PROKR1 Ishikawa cells. No elevation in LIF mRNA expression was observed in WT Ishikawa cells. Expression of LIF mRNA (C)
and protein (D) was measured after treatment with 40 nM PROK1 (lane 1) in the absence or presence of YM254890 (Gq
inhibitor, lane 2), BAPTA-AM (calcium inhibitor, lane 3), PKC inhibitor (Ro-318220, lane 4), cSrc inhibitor (PP2, lane 5), EGFR
inhibitor (AG1478, lane 6), or MEK inhibitor (PD98059, lane 7). PROK1-induced LIF mRNA and protein expression was
significantly inhibited in the presence of these inhibitors. Bars represent means  se of at least 3 independent experiments.
*P  0.05. ns, not significant; , absence of agent; , presence of agent.
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Figure 2. hCG mediates expression of LIF via induction of PROK1. Expression of PROK1 in baboon endometrium was elevated
after treatment with 1.25 IU of hCG/h for 5 d (A). Treatment of Ishikawa PROKR1 cells with 1 IU of hCG results in increased
expression of PROK1 which peaks at 6 h (B). Similarly, treatment of Ishikawa PROKR1 cells with 1 IU of hCG results in increased
expression of LIF, which peaks at 16 h (C). LIF mRNA expression in response to treatment with hCG is inhibited when PROKR1
Ishikawa cells are treated with 1 IU of hCG in the presence of cycloheximide (protein synthesis inhibitor) (D). PROKR1 Ishikawa
cells were transiently transfected with miRNA constructs targeting PROK1 or scrambled sequences and subsequently treated
with 1 IU of hCG. hCG-mediated PROK1 (E) and LIF (F) expression were significantly inhibited by PROK1 miRNA constructs.
Bars represent means  se of at least 3 independent experiments. *P  0.05.
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Nonpregnant endometrium and first trimester
decidua tissue express LH/CG receptor,
PROK1, and LIF
Using primers and probe directed against exon 11 of
the LH/CG receptor, we demonstrated elevated ex-
pression of the LH/CG receptor in first trimester
decidua samples obtained from wk 7–11 of pregnancy
compared with that in samples taken throughout the
normal menstrual cycle (P0.05) (Fig. 3A). PROK1
mRNA expression is significantly elevated in the secre-
tory phase compared with that in the proliferative
phase of the menstrual cycle (P0.05) (Fig. 3B) and is
further elevated in all samples collected during the first
trimester of pregnancy (P0.001) (Fig. 3B). Expression
of LIF mRNA is elevated in the midsecretory phase of
the menstrual cycle and in wk 7 of pregnancy compared
with that in nonpregnant proliferative or early secre-
tory endometrium and later stages of gestation
(P0.05) (Fig. 3C). To identify the site of expression of
the LH/CG receptor, PROK1, PROKR1, and LIF in
human first trimester decidua, immunofluorescent his-
tochemistry was used. Immunofluorescent histochemi-
cal analysis colocalized the site of expression of PROK1
(green) and the LH/CG receptor (red) to the glandu-
lar epithelial cells (yellow, merge) (Fig. 3D) of first
trimester decidua. By using an alternate antibody to the
LH/CG receptor (H-15, sc-25828; Santa Cruz Biotech-
nology) known to detect truncated variants of the
receptor, staining was also present in the stroma, data
not shown. In addition, expression of PROKR1 (green)
and LIF (red) colocalized to the glandular epithelial
cells (yellow, merge) of the decidua (Fig. 3E).
hCG mediates expression of PROK1 and LIF in first
trimester decidua tissue
To investigate the regulation of PROK1 by hCG in
first trimester decidua, decidual tissue was stimulated
with 1 IU of hCG. Temporal regulation of PROK1
mRNA expression by hCG was demonstrated with a
peak in expression of PROK1 at 6 h (2.10.2-fold
above control, P0.05) (Fig. 4A). Investigation of
Figure 3. Temporal expression and colocalization of signaling components. LH/CG receptor (A), PROK1 (B) and LIF (C)
mRNA in human endometrium across the menstrual cycle and first trimester decidua. P, proliferative; ES, early secretory; MS,
mid secretory, w7, w8, w9, w10, and w11 represent weeks of gestation (n	sample size from each stage of the cycle and early
pregnancy). Immunofluorescent histochemical analysis of the LH/CG receptor (red panel) and PROK1 (green panel) show
colocalization to the glandular epithelial cells of first trimester decidua (yellow panel, merge) (D). PROKR1 (green panel) and
LIF (red panel) colocalize to glandular epithelial cells and a subset of stromal cells of first trimester decidua (yellow panel,
merge) (E). Data are means  se. *P  0.05; ***P  0.001.
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hCG-mediated LIF mRNA expression in first trimester
decidua revealed a peak in LIF expression at 14 h
(1.980.27-fold above control, P0.05) (Fig. 4B). Incu-
bation of first trimester decidual tissue explants with
cycloheximide for 1 h before treatment with 1 IU of hCG
for 14 h significantly inhibited hCG-mediated LIF mRNA
expression (P0.05) (Fig. 4C), suggesting the involve-
ment of an intermediate protein in hCG-mediated LIF
expression. Infection of first trimester decidua explants
with lentivirus expressing PROK1-72 or PROK1-287
miRNA constructs significantly inhibited hCG-mediated
LIF mRNA expression compared with decidual explants
infected with lentivirus expressing miRNA negative con-
trol constructs (P0.05) (Fig. 4D).
PROK1 mediates expression of LIF in first trimester
decidual explants
Stimulation of first trimester decidual explants with
40 nM PROK1 demonstrated an elevation in LIF
mRNA expression at 6 h (2.990.53-fold above vehi-
cle-treated control, P0.05) (Fig. 5A) followed by a
peak in LIF protein production at 12 h (3.441.01-fold
above vehicle-treated control, P0.05) (Fig. 5B). These
data are consistent with those observed in the PROKR1
Ishikawa cell line, demonstrating that PROK1 regulates
LIF expression in decidual tissue. We further investigated
the signaling pathway inducing LIF expression in re-
sponse to PROK1. Cotreatment of first trimester de-
Figure 4. hCG mediates expression of LIF via induction of PROK1 in first trimester decidua. Treatment of first trimester decidua with
1 IU of hCG results in increased expression of PROK1 that peaks at 6 h (A). Similarly, treatment of first trimester decidua with 1 IU
of hCG results in increased expression of LIF that peaks at 14 h (B). LIF mRNA expression in response to treatment with hCG is
inhibited when first trimester decidua is treated with 1 IU of hCG for 14 h in the presence cycloheximide (protein synthesis inhibitor)
(C). First trimester decidua tissue was infected with lentivirus encoding miRNA constructs targeting PROK1 or a scrambled sequence.
Infected tissue was subjected to stimulation with 1 IU of hCG and subsequently analyzed for LIF mRNA expression. hCG-mediated
LIF expression was significantly inhibited by PROK1 miRNA constructs compared with scrambled sequences (D). Bars represent
means  se of at least 3 independent experiments. *P  0.05.
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cidual explants with inhibitors of Gq (YM254890),
Ca2 (BAPTA-AM), PKC (Ro-318220), cSrc (PP2),
EGFR (AG1478), or MEK (PD98059) significantly
inhibited PROK1-mediated LIF mRNA expression
(P0.05) (Fig. 5C).
PROK1-mediated LIF expression enhances
trophoblast adhesion
LIF has previously been described to enhance trophoblast
adhesion to extracellular matrices (16). We therefore
sought to investigate whether PROK1-mediated epithelial
LIF expression could induce trophoblast adhesion and
which components of the extracellular matrix were in-
volved. PROKR1 Ishikawa cells were treated with vehicle
or 40 nM PROK1 for 12 h, and conditioned medium was
collected. JEG-3 human trophoblast cells were subse-
quently treated overnight with conditioned medium from
vehicle- or PROK1-treated cells or conditioned medium
(vehicle- and PROK1-treated) that had been immunon-
eutralized using 1 g/ml LIF antibody, or treatment of
JEG-3 cells with 100 ng/ml recombinant LIF alone was
used as a positive control. Treatment of JEG-3 cells with
PROK1-conditioned medium enhanced adhesion to fi-
bronectin (Fig. 6A, lane 2) and laminin (Fig. 6B, lane 2)
matrices to a level comparable with that observed after
treatment with recombinant LIF protein alone (Fig. 6A, B;
lane 6). The adhesion mediated by PROK1-conditioned
medium was abrogated after immunoneutralization of
LIF from the medium (P0.05) (Fig. 6A, B; lane 4).
These data suggest that PROK1-mediated LIF expression
may enhance trophoblast-endometrium adhesion.
DISCUSSION
Preimplantation signaling between the developing blas-
tocyst and the endometrium is essential for successful
implantation and maintenance of early pregnancy.
Endometrial cytokines prepare the endometrium to
Figure 5. PROK1 induces LIF expression in first trimester
decidua. Treatment of first trimester decidua with 40 nM
PROK1 induced LIF mRNA (A) and protein (B) expres-
sion that peaked at 6 and 12 h, respectively. Expression of
LIF mRNA in first trimester decidua was measured after
treatment with 40 nM PROK1 (lane 1) in the absence or
presence of YM254890 (Gq inhibitor, lane 2), BAPTA-AM
(calcium inhibitor, lane 3), PKC inhibitor (Ro-318220, lane
4), cSrc inhibitor (PP2, lane 5), EGFR inhibitor (AG1478,
lane 6), or MEK inhibitor (PD98059, lane 7) (C). PROK1-
induced LIF mRNA expression was significantly inhibited
in the presence of these inhibitors. Bars represent means
se of at least 3 independent experiments. *P  0.05.
2172 Vol. 23 July 2009 EVANS ET AL.The FASEB Journal
become receptive to the blastocyst, and increasing
evidence suggests that paracrine and juxtacrine signals
from the blastocyst can influence the endometrial
cytokine milieu and enhance receptivity. Blastocysts are
known to secrete various factors (reviewed in ref. 17)
that initiate early embryonic communication with the
endometrium. There is evidence that embryonic hCG
can influence implantation by regulating the expres-
sion of endometrial factors that are important in recep-
tivity, such as endometrial LIF (13–15, 18, 19).
LIF has been shown to be critical in murine implan-
tation (9, 20) and has been suggested to have a role in
human fertility (21, 22). We have previously demon-
strated regulation of a host of implantation-related
genes including LIF by PROK1 using gene array analy-
sis (7). We demonstrate that the temporal expression of
LIF mRNA and protein is regulated by PROK1 in an
endometrial epithelial cell line and in first trimester
decidual tissue explants. LIF is known to be regulated
by cytokines including TNF, IL-1, and TGF-
 via acti-
vation of a signaling cascade involving intracellular
calcium, PKC, and MEK (23–27). To examine whether
PROK1 activates LIF expression through a similar path-
way, chemical inhibitors of signaling pathway molecules
were used. We demonstrate that PROKR1, a Gq-cou-
pled receptor that mediates extracellular signal-regu-
lated kinase 1/2 phosphorylation (7), induces LIF
expression via a cSrc-EGFR-MEK signaling pathway,
and is also dependent on intracellular calcium release
in both PROKR1 Ishikawa cells and first trimester
decidual explants.
This study demonstrates that hCG mediates both
PROK1 and LIF expression with a delay in the peak of
LIF expression after the peak in PROK1 expression. By
using an inhibitor of protein synthesis, hCG induction
of LIF was abolished suggesting the involvement of
PROK1 as an intermediate in hCG-mediated LIF ex-
pression. Using miRNA constructs targeting PROK1, we
confirmed that hCG-stimulated LIF expression is de-
pendent on expression of PROK1. These data provide
the first evidence that an intermediate protein, PROK1,
is required in hCG-mediated endometrial LIF expres-
sion.
To demonstrate that the data represent an active sig-
naling pathway in vivo LH/CG receptor is required to be
present and colocalized in the endometrium and decidua
to permit up-regulation of PROK1 via hCG. We therefore
investigated the expression of the LH/CG receptor in our
decidua samples using quantitative PCR. The results dem-
onstrated the expression of the receptor in the normal
cycling endometrium, with an elevation in expression in
first trimester decidua. To demonstrate LH/CG receptor
mRNA translation and localization, immunohistochemi-
cal analysis of first trimester decidua was performed with
an antibody recognizing the full-length receptor. This
confirmed protein expression of the receptor with local-
ization to the glandular epithelial cells. Coexpression of
PROK1 and LH/CG receptor was demonstrated in first
trimester decidual tissue, suggesting potential regulation
of PROK1 by hCG in vivo. Furthermore, the colocalization
of PROKR1 and LIF in first trimester decidual tissue
suggests that the pathway we have identified, hCG-
LH/CG receptor binding activating PROK1-PROKR1 sig-
naling, is responsible for regulation of LIF expression in
human early pregnancy.
LIF expression was elevated in midsecretory endome-
trium and during early pregnancy up to wk 7 in first
trimester decidua. LIF expression significantly de-
creased thereafter, in agreement with previous reports
that decidual LIF production is decreased in the sec-
Figure 6. PROK1 via LIF increases adhesion of trophoblast cells to fibronectin and laminin. Treatment of JEG-3 trophoblast cells
with LIF increased adhesion to fibronectin (A, lane 6) and laminin (B, lane 6) compared with vehicle-treated cells (A, B; lane
5). Treatment of JEG-3 cells with conditioned medium collected from PROKR1 Ishikawa cells treated with 40 nM PROK1 for
24 h (PROK1 CM) also increased adhesion to fibronectin (A, lane 2) and laminin (B, lane 2) compared with conditioned
medium collected from PROKR1 Ishikawa cells treated with vehicle for 24 h (vehicle CM; A, B; lane 1). This PROK1-mediated
adhesion was abolished when LIF was immunoneutralized from the PROK1-conditioned medium (A, B; lane 4). Bars represent
means  se of at least 3 independent experiments. *P  0.05. Ab, immunoneutralization.
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ond trimester compared with that in the first trimester
(28). Week 8 of pregnancy shows a shift in the pheno-
type of the trophoblasts from predominantly an an-
choring villi to an increase in invasive interstitial tro-
phoblasts (29, 30). By 8 wk of pregnancy the interstitial
trophoblasts have invaded to the decidual-myometrial
border and during the second trimester, there is a
further invasion into the inner myometrium (29, 30).
In first trimester trophoblast populations, LIF has been
suggested to increase fibronectin production, inhibit
gelatinase activity, increase spreading and adhesion,
and induce differentiation toward syncytialization (31–
33). Our data confirm a role for LIF in enhancing
adhesion of trophoblast cells to fibronectin and lami-
nin mediated via PROK1-PROKR1 signaling. At the
interface between the chorionic villi and the decidua at
the implantation site, a predominantly acellular zone
develops, known as Nitabuch’s fibrinoid (34). This
zone is rich in laminin, suggesting that PROK1-induced
LIF promotes adhesion of the anchoring trophoblast
cells to this layer (35). Down-regulation of LIF in
decidua after wk 7 of pregnancy may be controlled by
the trophoblast as a requirement to reduce adhesion
and allow controlled invasion through the decidua.
Therefore, PROK1 enhancement of LIF may only be
required during early pregnancy before wk 8 of gesta-
tion during the establishment of the anchoring villi. In
addition, decidualizing stromal cells also produce a
pericellular laminin basement membrane that may
regulate this process (36). The increase in PROK1 and
LIF in the midsecretory phase of the menstrual cycle
and enhancement before implantation may also regu-
late trophoblast adhesion. The basal lamina associated
with the epithelium increases in thickness during the
secretory phase, reaching maximum thickness in the
midsecretory phase. The basal lamina consists of colla-
gen type IV with proteoglycan molecules such as lami-
nin and fibronectin (37). The thickened basal lamina
may provide an important structural scaffold for epi-
thelial and trophoblast attachment. A number of stud-
ies suggest that LIF production in fertile women is
elevated in the secretory phase of the menstrual cycle
compared with that in the proliferative phase of the
cycle but is dysregulated in infertile women (22, 38–
40). Therefore, disrupted regulation of PROK1 expres-
sion and its downstream target LIF may be associated
with infertility, spontaneous abortion, and placental
abnormalities.
In conclusion, this study demonstrates that embry-
onic hCG regulates endometrial PROK1-PROKR1 sig-
naling, which induces expression of LIF via induction
of intracellular calcium and activation of intracellular
phosphorylation cascades. These data support a role
for PROK1 in initial blastocyst adhesion to basement
membrane matrices and subsequent trophoblast inva-
sion. Dysregulation in the expression of PROK1 and
consequently LIF may lead to suboptimal fertility and
trophoblast invasion.
We thank Sharon Donaldson and Catherine Murray for
consenting patients and tissue collection.
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